FMP
Silexion Therapeutics LTD
SLXN
NASDAQ
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
0.827 USD
0.0033 (0.399%)
About
ceo
Mr. Ilan Hadar M.B.A.
sector
Healthcare
industry
Biotechnology
website
https://silexion.comexchange
NASDAQ
Description
Silexion Therapeutics LTD, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
CIK
0002022416
ISIN
KYG1281K1067
CUSIP
N/A
Address
The Goldyne Savad Institute of...
Phone
972 2 674 3430
Country
IL
Employee
N/A
IPO Date
Aug 16, 2024
Key Executives
Name
Title
Pay
Year Born
Mr. Ilan Hadar M.B.A.
Chairman & Chief Executive Officer
253.61k
1969
Dr. Mitchell Shirvan M.B.A., Ph.D.
Chief Scientific & Development Officer
206.8k
1954
Ms. Mirit Horenshtein Hadar
EVice President of Finance Affairs, Chie...
69.98k
1984
As of December 31, 2024, the total employee count stands at N/A, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.
